VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMS 2022 | An update on Alliance A061202: addition of ixazomib to pomalidomide-dexamethasone in R/R myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an update on the Alliance A061202 study (NCT02004275), which is a randomized Phase II study evaluating the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma refractory to lenalidomide. When ixazomib was administered early, there was a striking progression-free survival (PFS) benefit of 21 months for the triplet drug combination versus 7.5 months for the control group. When ixazomib was added later, the PFS gain was ~6 months, suggesting that ixazomib provides a greater benefit when administered early. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter